

Market Announcement

29 April 2025

MedAdvisor Limited (ASX: MDR) – Suspension from Quotation

Description

The securities of MedAdvisor Limited ('MDR') will be suspended from quotation immediately under Listing Rule 17.2, at the request of MDR, pending the release of an announcement regarding a pending Court application under section 1322 of the Corporations Act 2001 (Cth) deeming the cleansing notice lodged on the ASX Market Announcements Platform on 23 April 2025 ('Cleansing Notice') to be effective from the date of issue of the shares the subject of the Cleansing Notice.

Issued by

ASX Compliance

Ms Vanessa Nevjestic
Listings Compliance (Perth)
ASX Limited
Level 40, Central Park
152-158 St George's Terrace
Perth WA 6000

29 April 2025

Dear Ms Nevjestic

MedAdvisor Limited (ASX:MDR) – Request for Voluntary Suspension

Pursuant to ASX Listing Rule 17.2, MedAdvisor Limited ACN 145 327 617 (**Company**) requests that the ASX grants voluntary suspension with respect to the Company's shares.

The Company provides the following information regarding this request:

1. The reason for the voluntary suspension is that the Company intends to make an announcement regarding a pending Court application under section 1322 of the *Corporations Act 2001*(Cth) deeming the cleansing notice lodged on the ASX Market Announcements Platform by the Company on 23 April 2025 (**Cleansing Notice**) to be effective from the date of issue of the shares the subject of the Cleansing Notice (**Court Application**). The voluntary suspension is required to prevent the trading of the Company's shares the subject of the Cleansing Notice until such time as the Court Application has been determined.
2. The Company requests a voluntary suspension of the Company's securities from the commencement of trading on Tuesday, 29 April 2025 until the earliest of:
 - (a) such time as the Company makes an announcement to the market in relation to the outcome of the Court Application; and
 - (b) the Company separately requests that the voluntary suspension be lifted.
3. The Company expects that the ASX announcement about the outcome of the Court Application will be made before open of trading on Friday, 2 May 2025.
4. The Company considers that the voluntary suspension is necessary as otherwise trading in the Company's shares would continue on an uninformed basis.

5. The Company is not aware of any reason why a voluntary suspension should not be granted or any other information necessary to inform the market about the requested voluntary suspension.

Yours sincerely

A handwritten signature in black ink, appearing to read 'Gillian Nairn', written in a cursive style.

Gillian Nairn

Company Secretary

MedAdvisor Limited